As consumers become increasingly aware of the role of the microbiome in overall health and wellness, the demand for high-quality probiotics continues to rise
Gnosis by Lesaffre has launched a new product in its probiotic range: LifeinU L.Rhamnosus GG 350, a new quality specification of our existing reference probiotic bacteria LifeinU L.Rhamnosus GG.
Lactobacillus rhamnosus GG is used in various products worldwide to support digestive health by restoring and maintaining a balanced gastrointestinal flora, protecting the gut from antibiotic-associated diarrhea, and protecting against acute diarrhea.
As consumers become increasingly aware of the role of the microbiome in overall health and wellness, the demand for high-quality probiotics continues to rise. Gnosis is committed to researching and developing microorganisms, with a particular focus on bacteria.
“This launch represents an important step for Gnosis and Lesaffre Group, as it underscores our commitment to developing a comprehensive bacterial offering that covers all microorganism kingdoms, including yeast, bacteria, and bacteriophages,” said Philippe Caillat Gnosis’ Global Marketing Director. “We believe that this approach will enable us to offer our customers a truly integrated and holistic approach to microbiome health.”
As Gnosis is committed to sustainability, the biotransformation process that we use to produce LifeinU L.Rhamnosus GG 350 is a promising opportunity for industries
One of the key features of the new LifeinU L.Rhamnosus GG 350 product is its reliability. Gnosis has invested significant time and resources in developing a high-quality specification that is in line with market standards: 350.109 CFU/g. Additionally, the company’s proprietary production process ensures consistent and robust stability over time, giving customers the confidence that they are getting a consistently effective product.
“At Gnosis, we pride ourselves on our expertise in biotechnology and yeast research, with over 170 years of experience in the field. This expertise has been instrumental in the development of our new probiotic product, and we are confident that it will provide an adapted response to our clients’ needs,” said Caillat.
“As Gnosis is committed to sustainability, the biotransformation process that we use to produce LifeinU L.Rhamnosus GG 350 is a promising opportunity for industries to reduce their raw material consumption and operate more sustainably,” he concluded. “We believe that this approach enables industries to reduce their impact on the environment while encouraging customers to consume more responsibly.”